We're accelerating the delivery of the next generation of medicines to the patients who need them.
Our development portfolio contains 12 small molecules and 11 biotherapeutic agents. In addition to the agents below, we have two additional undisclosed programmes currently in development: a small molecules combination and a protein degrader.
Download the full pipelineAgent (trial) | Technology and target | Partnerships | Indications | Phase |
Peptide / Wnt, beta-catenin | Adrenocortical carcinoma | Preclinical | ||
Antibody / TROP2 | Solid tumours | Preclinical | ||
BITE / ROR1, CD3 | Solid tumours | Preclinical | ||
BITE / ROR1, CD3 | Lymphoma | Trial set up | ||
Protein / CD19, CD20 | Lymphoma | Phase 1/2 | ||
Antibody / HER3 | HER3 positive solid tumours, prostate | Phase 1/2 (closed in follow up) | ||
Antibody / HLA-G1 | Solid tumours, renal | Phase 1/2 | ||
Vaccine / MAGE3, NY-ESO-1 | Barinthus Biotechnology / Ludwig Institute for Cancer Research | Lung | Phase 1/2 (closed in follow up) | |
Antibody / PDL1 | Rare adult, paediatric, teenage and young adult cancer | Phase 2 | ||
Antibody / Gremlin1 | Pancreatic | Phase 2 | ||
Antibody combi / HER2 | Rare adult, paediatric, teenage and young adult cancer | Phase 2 |
Agent (trial) | Target | Partnerships | Indications | Stage |
|---|---|---|---|---|
MT1-MMP | Solid tumours | Phase 1/2 (closed) | ||
EP4 | Solid tumours, colorectal, prostate, gastric, oesophageal, renal | Phase 1/2 | ||
Cdc7 | Solid tumours | Phase 1 (closed) | ||
Adenosine / A2BR | Solid tumours | Phase 1/2 | ||
ALK, TK1 | Rare adult, paediatric, teenage and young adult cancer | Phase 2 | ||
cMET, HGFR | Rare adult cancer | Phase 2 | ||
ROS1, TRK, ALK | Rare adult, paediatric, teenage and young adult cancer | Phase 2 | ||
BRAF, MAP, MEK | Rare adult cancer | Phase 2 |
Discover the latest news and press releases related to our work, including partnering, clinical trials and patient involvement activities.
We partner with academics, pharmaceutical and biotech companies worldwide to develop novel cancer treatments. Learn more about the opportunities to partner with us.
DETERMINE is the first UK national precision medicine trial in rare cancers, testing a range of therapies targeting key genetic changes in cancer cells.
